Schirmer Uwe, Doberstein Kai, Rupp Anne-Kathleen, Bretz Niko P, Wuttig Daniela, Kiefel Helena, Breunig Christian, Fiegl Heidi, Müller-Holzner Elisabeth, Zeillinger Robert, Schuster Eva, Zeimet Alain G, Sültmann Holger, Altevogt Peter
Department of Translational Immunology, German Cancer Research Center.
Oncotarget. 2014 Jan 30;5(2):462-72. doi: 10.18632/oncotarget.1552.
L1CAM promotes cell motility, invasion and metastasis formation in various human cancers and can be considered as a driver of tumor progression. Knowledge about genetic processes leading to the presence of L1CAM in cancers is of considerable importance. Experimentally, L1CAM expression can be achieved by various means. Over-expression of the transcription factor SLUG or treatment of cells with TGF-β1 can induce or augment L1CAM levels in cancer cells. Likewise, hypomethylation of the L1CAM promoter on the X chromosome correlates with L1CAM expression. However, presently no mechanisms that might control transcriptional activity are known. Here we have identified miR-34a as a suppressor of L1CAM. We observed that L1CAM positive endometrial carcinoma (EC) cell lines HEC1B and SPAC1L lost L1CAM protein and mRNA by treatment with demethylating agents or knock-down of the DNA-methyltransferase-1 (DNMT1). Concomitantly, several miRNAs were up-regulated. Using miRNA profiling, luciferase reporter assays and mutagenesis, we identified miR-34a as a putative binder to the L1CAM-3'UTR. Over-expression of miR-34a in HEC1B cells blocked L1CAM expression and inhibited cell migration. In ECC1 cells (wildtype p53) the activation of p53 caused miR-34a up-regulation and loss of L1CAM expression that was miR-34a dependent. We observed an inverse correlation between L1CAM and miR-34a levels in EC cell lines. In primary tumor sections areas expressing high amounts of L1CAM had less miR-34a expression than those with low L1CAM levels. Our data suggest that miR-34a can regulate L1CAM expression by targeting L1CAM mRNA for degradation. These findings shed new light on the complex regulation of L1CAM in human tumors.
L1细胞粘附分子(L1CAM)在多种人类癌症中促进细胞运动、侵袭和转移形成,可被视为肿瘤进展的驱动因素。了解导致癌症中出现L1CAM的遗传过程具有相当重要的意义。在实验中,L1CAM的表达可通过多种方式实现。转录因子SLUG的过表达或用转化生长因子-β1(TGF-β1)处理细胞可诱导或增强癌细胞中L1CAM的水平。同样,X染色体上L1CAM启动子的低甲基化与L1CAM表达相关。然而,目前尚不清楚可能控制转录活性的机制。在此,我们已确定miR-34a是L1CAM的抑制剂。我们观察到,L1CAM阳性的子宫内膜癌(EC)细胞系HEC1B和SPAC1L通过用去甲基化剂处理或敲低DNA甲基转移酶-1(DNMT1)而失去L1CAM蛋白和mRNA。同时,几种微小RNA(miRNA)被上调。通过miRNA谱分析、荧光素酶报告基因测定和诱变,我们确定miR-34a是L1CAM 3'非翻译区(UTR)的假定结合物。miR-34a在HEC1B细胞中的过表达阻断了L1CAM的表达并抑制了细胞迁移。在ECC1细胞(野生型p53)中,p53的激活导致miR-34a上调以及L1CAM表达缺失,且该缺失依赖于miR-34a。我们在EC细胞系中观察到L1CAM和miR-34a水平呈负相关。在原发性肿瘤切片中,与L1CAM水平低的区域相比,表达大量L1CAM的区域miR-34a表达较少。我们的数据表明,miR-34a可通过靶向L1CAM mRNA进行降解来调节L1CAM的表达。这些发现为人类肿瘤中L1CAM的复杂调控提供了新的线索。